NCT06575790

Brief Summary

The goal of this trial is to evaluate blood sugar control in patients with type 1 diabetes when using a simple meal bolus strategy (small, medium, large meals) compared to carbohydrate counting when on a hybrid closed loop system. The main question it aims to answer are: What is the blood sugar time in range when using simple meal boluses versus carbohydrate counting? Participants will: Use the simple meal bolus plan for 4 weeks. Do precise carbohydrate counting for 4 weeks. Provide their continuous glucose monitor and pump data Take surveys about the experience of meal bolusing during the study

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 23, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 28, 2024

Completed
3 months until next milestone

Study Start

First participant enrolled

November 25, 2024

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2025

Completed
Last Updated

December 10, 2024

Status Verified

December 1, 2024

Enrollment Period

10 months

First QC Date

August 23, 2024

Last Update Submit

December 5, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Time in Range

    % of time sensor glucose values are between 70-180 mg/dL

    Measured during the duration of the study period, up to 12 weeks

Secondary Outcomes (3)

  • Hypoglycemia

    Measured during the duration of the study period, up to 12 weeks

  • Hyperglycemia

    Measured during the duration of the study period, up to 12 weeks

  • Feasibility, acceptability, and self-reported mealtime insulin bolus burden

    Given 3 times during the duration of the study period, up to 12 weeks

Study Arms (2)

Simple Meal Bolusing

EXPERIMENTAL

Participants will be instructed to enter a set number of carbohydrates before meals based on if they are having a small, medium, or large meal. The preset numbers for meals will be based on their average total daily dose (TDD) determined during the 2-week usual care observation period. The participants will have their insulin to carbohydrate ratios set based on the standard formula of 450/TDD for all meals initially (e.g. a child with a TDD of 50 u/day would have 450/50=9 so an I:C of 1:9). They enter a carbohydrate amount of 30 g for small meals, 60 g for regular meals, and 90 g for large meals.

Behavioral: Simple Meal Bolusing

Precise Carbohydrate counting

ACTIVE COMPARATOR

Participants will be instructed to enter a precise carbohydrate count before meals to the best of their ability. Pump settings may be adjusted per provider discretion and typical clinical care during this time period.

Behavioral: Carbohydrate counting

Interventions

Participants will enter pre-determined numbers for small, medium, or large carbohydrate meals rather than using precise carbohydrate counting

Simple Meal Bolusing

Participants will be instructed to enter accurate carbohydrate counts to the best of their ability for all meals and snacks

Precise Carbohydrate counting

Eligibility Criteria

Age14 Years - 26 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Clinical diagnosis of T1D of at least 1 year duration
  • Using a commercial HCL system
  • Willingness to not start any new non-insulin glucose-lowering agent during trial
  • Willingness to participate in all study procedures
  • Investigator has confidence that participant can successfully operate all study devices and adhere to protocol

You may not qualify if:

  • History of \>1 severe hypoglycemic event with seizure or loss of consciousness in the last 6 months or \>1 DKA event in the last 6 months not related to illness or infusion set failure
  • History of chronic renal disease or currently on hemodialysis, adrenal insufficiency, hypothyroidism that is not adequately treated, use of oral or injectable steroids within the last 8 weeks, or known ongoing adhesive intolerance
  • A condition, which in the opinion of the investigator or designee, would put the participant or study at risk
  • Participation in another interventional trial at the time of enrollment
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Barbara Davis Center

Aurora, Colorado, 80045, United States

RECRUITING

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 23, 2024

First Posted

August 28, 2024

Study Start

November 25, 2024

Primary Completion

September 30, 2025

Study Completion

September 30, 2025

Last Updated

December 10, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

Locations